Cancers & treatments·Regimen libraryFirst line

Docetaxel + prednisone

Checked 2026-09-09

Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 (hormone-sensitive); up to 10 (castration-resistant) (about 18 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Docetaxel Cytotoxic chemotherapy (taxane)	75 mg/m²	IV	D1
Prednisone	5 mg twice daily	Oral	D1-21

Cycles

6 (hormone-sensitive); up to 10 (castration-resistant)

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Consider (10-20% FN risk)

Notes

ARASENS adds darolutamide 600 mg twice daily; PEACE-1 adds abiraterone.

Used in

Prostate cancer

Trials

CHAARTED (E3805)ARASENS PEACE-1

Products

Docetaxel

Source

TAX 327, NEJM 2004; CHAARTED, NEJM 2015

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Cabazitaxel + prednisone

Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor

every 21 days

Abiraterone + prednisone with ADT

High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer

every 28 days

177Lu-PSMA-617

PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane

every 42 days × 6

Olaparib maintenance

Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum

every 28 days × 2

All regimens Cabazitaxel + prednisone →